Navigation Links
Viprinex in Medical News

Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results

...and to proceed expeditiously in the process," stated William Fletcher, acting Chief Executive Officer. Assuming accrued costs associated with the viprinex program are fully paid off by June 30, 2009 as currently estimated, the Company expects to end its fiscal year with approximately $23 million in cash,...

Neurobiological Technologies Reports Second Quarter Financial Results

...ently in two Phase III clinical trials. We believe viprinex has the potential to double the treatment window o...aZeneca's neuroprotectant drug candidate." About viprinex Phase 3 Trial Program viprinex is an investigational agent with multiple novel me...

Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ

...ng drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The company is currently developing viprinex (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. http://www.ntii.com A registrati...

Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke

...inex(TM) (ancrod), for the treatment of acute ischaemic stroke at the 16th annual European Stroke Congress in Glasgow, Scotland in the United Kingdom. viprinex is a defibrinogenating agent derived from the venom of the Malayan pit viper. "The ancrod data presented this week in Glasgow draws positive c...
Viprinex in Medical Technology

Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data

- Company Plans to Announce Interim Results in January 2009 and Final Trial Data in mid-2009 - EMERYVILLE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that following a meeting with the U.S. Food ...

Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)

Investigational Drug Being Pursued for the Treatment of Ischemic Stroke GLASGOW, Scotland, May 31, 2007 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI) announced today the presentation of new analysis of data from prior clinical trials of ancrod and updates on the clinical devel...

Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis

...an acute ischemic stroke, comparing treatment with viprinex to treatment with placebo. The DSMB determined tha...he study. "We are deeply disappointed that viprinex did not improve overall patient outcomes in our cl...adcount if we determine that future development of viprinex is not warranted." About Neurobiological T...

Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials

...coauthor of the retrospective analysis. "Earlier viprinex trials used a dosing regimen that infused the drug...urrently conducting two Phase 3 clinical trials of viprinex to investigate whether ancrod can safely and effec...have enrolled over 500 patients. NTI believes that viprinex can be administered up to six hours after the onse...

Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials

... interim analysis across the two studies. NTI is currently studying whether viprinex is safe and effective for treating acute ischemic stroke when given within ...as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to double th...

Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference

...rth American and European Phase 3 stroke trials of viprinex involving more than 1,700 patients. viprinex has been shown to rapidly reduce blood levels of f...enefit from this approach. "The prior studies of viprinex showed improved efficacy, but used a dosing regime...

Fifth DSMB Meeting Supports Neurobiological Technologies' Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)

...nctional outcome at 3 months. This is the fifth DSMB meeting for the Ancrod Stroke Program (ASP). The two trials are: -- ASP-I, the Study of Acute viprinex for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod in Subjects Beginning Treatment Within 6 Hours of the Ons...
Viprinex in Biological Technology

Neurobiological Technologies Announces Suspension of Viprinex Development

EMERYVILLE, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII ) (NTI(R)) today announced that, following a detailed analysis of the recent interim results of the Viprinex(TM) clinical trial, the company has decided not to develop Viprinex further for ...

Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program

EMERYVILLE, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today announced it will hold a conference call on Monday, October 13, to provide an update on the Viprinex(TM) (ancrod) Phase 3 Trial Program for acute ischemic stroke. Hosting t...

Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009

...l drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifica... sale of XERECEPT(R) by Celtic, the development of viprinex for acute ischemic stroke by NTI, delays or other ...blems with our clinical trials, the outcome of the viprinex interim analysis, the time and costs for obtaining...

Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results

...eiman, president and chief executive officer. "The viprinex studies have recently surpassed a total of 600 pat... will constitute a major go/no-go decision for the viprinex program, since it is the first efficacy assessment...ring Board (DSMB). For the trial to pass futility, viprinex must demonstrate predetermined efficacy criteria. ...

Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. NTI...

Neurobiological Technologies Sets Date for First Quarter Financial Results

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acu...

Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acu...

Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. NTI...

Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acu...

Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine

... advanced product candidate, Viprinex(TM) (ancrod), is in phase 3 clinical testing as a novel investigational drug for treating acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acu...
Other Tags
(Date:9/17/2014)... -- Present-day Europeans are the descendants of at ... a new study. Previous research suggested ... European farmers. But, a new genetic analysis involving ... descendants of Ancient North Eurasians. Nearly all present-day ... group, researchers from Harvard Medical School said. , ...
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Managing diabetes, ... a healthy weight can reduce the risk for dementia ... The World Alzheimer Report 2014, commissioned by ... risk of dementia by 50 percent. The study noted ... factors for diabetes as well as high blood pressure. ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, ... to artificial sweeteners to soothe their sweet tooth may ... study suggests. Artificial sweeteners can potentially make blood ... in human and mouse studies. That,s because saccharine ... in the intestines in ways that can impair some ...
(Date:9/17/2014)... COLUMBUS, Ohio Mathematics might be able to reduce ... damage related to the autoimmune disease lupus. , In ... can predict the progression from nephritis kidney inflammation ... current treatments cannot reverse. A kidney biopsy is the ... the damage and its extent. , The model could ...
(Date:9/17/2014)... Research has shown that most 18-month-olds learn an average ... little is known about how children process information to ... years. In a new study, a University of Missouri ... they age, and a limit exists as to how ... could help parents enhance their children,s vocabularies and assist ...
Breaking Medicine News(10 mins):Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 2Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 3Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2Health News:Babies learn words differently as they age, researcher finds 2
(Date:9/17/2014)... on a Carnegie expedition in Australia,s Great Barrier Reef ... since the mid-1970s. The scientists suggest that ocean acidification ... slowdown. , In a quest for historical context ... current measurements of the growth rate of a section ... more than 30 years ago. Their work is published ...
(Date:9/17/2014)... of bacterial infections, including MRSA and MSSA could ... bumps that mimic the scaly surface of shark ... access journal Antimicrobial Resistance and Infection Control ... materials prevented the spread of human disease bacteria ... Sharklet, is an arrangement of ridges formulated to ...
(Date:9/16/2014)... Hopkins neuroscientists have discovered the "molecular brakes" that time ... cochleas of mice. These "hair cells" translate sound waves ... and are interpreted as sounds. If the arrangement of ... A summary of the research will be published in ... , "The proteins Hey1 and Hey2 act as brakes ...
Breaking Biology News(10 mins):Coral growth rate plummets in 30-year comparison 2Sharks' skin has teeth in the fight against hospital superbugs 2Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
Other Contents